Analyzing T2 Biosystems (NASDAQ:TTOO) and Vasamed (OTCMKTS:VSMD)

T2 Biosystems (NASDAQ:TTOO) and Vasamed (OTCMKTS:VSMD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Insider and Institutional Ownership

23.2% of T2 Biosystems shares are owned by institutional investors. 0.1% of T2 Biosystems shares are owned by insiders. Comparatively, 8.0% of Vasamed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for T2 Biosystems and Vasamed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
T2 Biosystems	0	1	0	0	2.00
Vasamed	0	0	0	0	0.00

T2 Biosystems currently has a consensus price target of $5.00, indicating a potential upside of 1,328.57%. Given T2 Biosystems’ stronger consensus rating and higher possible upside, equities research analysts clearly believe T2 Biosystems is more favorable than Vasamed.

Earnings & Valuation

This table compares T2 Biosystems and Vasamed”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
T2 Biosystems	$7.68 million	0.96	-$50.08 million	N/A	N/A
Vasamed	N/A	N/A	N/A	N/A	N/A

Vasamed has lower revenue, but higher earnings than T2 Biosystems.

Profitability

This table compares T2 Biosystems and Vasamed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
T2 Biosystems	-563.16%	N/A	-174.06%
Vasamed	N/A	N/A	N/A

Risk & Volatility

T2 Biosystems has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, Vasamed has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.

About T2 Biosystems

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

About Vasamed

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.